ASEAN Records is proud to officially recognise NXTVISION for achieving a significant milestone in the healthcare and nutraceutical sector, as the: First Joint Supplement with the Highest Arthritis Relief and Joint Stiffness Reduction Demonstrated in a 12-Week Clinical Trial (Randomized, placebo-controlled trial with 108 subjects: Stiffness ↓51%, Disability ↓41%, WOMAC ↑37%, Inflammation ↓up to 12%)
This recognition highlights Flexy3’s strong scientific foundation and its unprecedented clinical outcomes—setting a new benchmark for measurable efficacy in joint wellness across the ASEAN region.
A Scientifically Validated Advancement in Joint Health
Flexy3 stands out as one of the few joint supplements in the region supported by a randomized, placebo-controlled human clinical trial, demonstrating exceptional improvements in:
- Joint stiffness reduced by 51%
- Disability scores reduced by 41%
- WOMAC function scores improved by 37%
- Markers of inflammation reduced by up to 12%
These results position Flexy3 as a leading innovation in joint mobility enhancement, inflammation management, and long-term musculoskeletal support—bridging evidence-based science with consumer wellness.
The achievement reflects NXTVISION’s commitment to clinical integrity, research-driven formulation, and elevating industry standards in the joint health category.
A Milestone Moment of Recognition
The official ASEAN Records certificate was presented on 22 October 2025 at the Andaman Grand Ballroom, Kuala Lumpur, during the ASEAN Records Gala Night 2025.
The certificate was proudly received by Teoh Wei Ken, Chief Executive Officer, and Jane Andrea Leow, Managing Director, in recognition of their leadership and the team’s dedication to advancing joint health solutions backed by scientific excellence.
A Message from the Leadership
Reflecting on this milestone, Teoh Wei Ken, Chief Executive Officer of NXTVISION shared:
About ORIACTIV™ & NXTVISION
ORIACTIV™ Flexy3 is part of NXTVISION’s growing portfolio of scientifically developed wellness solutions focused on functional improvements, long-term mobility, and healthier ageing.
NXTVISION continues to invest heavily in:
- clinically validated ingredient technologies
- research partnerships
- measurable outcome-driven formulations
- consumer education for sustainable joint wellness
With Flexy3’s ASEAN Records recognition, the company strengthens its position as a forward-thinking leader in the joint health and nutraceutical industry.
For more information: https://oriactivflexy3.com/about-us
